Research & Development: Page 80
-
PharmaVoice Team/PharmaVoice
PharmaTrax
50 J u l y 20 03 PharmaVOICE PHARMA TRAX SALES, MARKETING, AND R&D TRENDS AFFECTING THE HEALTHCARE INDUSTRY Study Suggests Physicians Want to Hear from REPSWITH OBJECTIVE INFORMATION A study from J. Scott International Inc. suggests that doctors are more likely to write prescriptions if they ...
By PharmaVoice Team • April 10, 2008 -
PharmaVoice Team/PharmaVoice
PharmaOutlet
In nearly every aspect of today’s society, we enjoy the benefits and the efficiencies of technology’s impact. We buy theater and plane tickets online, travel with directions from global posi tioning satellites, and accomplish everything from paying bills to making dinner reservations and then ins...
By John M. Hudak • April 10, 2008 -
Explore the Trendline➔
Stock via Getty Images
TrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Raise Your Voice: Letters
RAISE your voice Resultsoriented partnerships We read with great interest the incisive recommendations of our friend Richard B. Vanderveer, CEO of V2 Inc., on the need to redefine the drivers of and acquisition process es for successful pharmaceutical company/ven dor relationships. (“The shifting...
By PharmaVoice Team • April 10, 2008 -
PharmaVoice Team/PharmaVoice
Global Clinical Connections
Building Relationship Bridges Forming a winning CRO/sponsor partnership requires trust, communication, and understand ing the expectations and needs of the other party. Using advanced technology for communi cations, taking ownership, and getting to know your partner can ensure these elements are ...
By Robin Robinson • March 31, 2008 -
PharmaVoice Team/PharmaVoice
Last Word
James King,M.D.,FAAFP,was named Presidentelect of the American Academy of Family Physicians (AAFP) in September 2006.Previously,he served three years as a director on the AAFP board.He also serves as volunteer faculty at the University of Tennessee Center for Health Sciences, is on the medical st...
By PharmaVoice Team • March 29, 2008 -
PharmaVoice Team/PharmaVoice
On the Calendar
Managing MultiJurisdictional Legal and Regulatory Risks in Clinical Trials Renaissance Brussels Hotel,Brussels,Belgium For more information, contact Cordelia Ekeocha,C5,at 442078786929, email [email protected], or visit c5online.com. April 16–17 Pharma Marketing Research Essentials Seminar S...
By PharmaVoice Team • March 29, 2008 -
PharmaVoice Team/PharmaVoice
E-Media
NEW ELECTRONIC AND WEBBASED APPLICATIONS, SITES, AND TECHNOLOGIES Clinical Ink has introduced clinicalink.com, a Website that provides corporate information and detailed explanations of the Clinical Ink eSource solution for the electronic capture and storage of data during clinical trials. The co...
By PharmaVoice Team • March 29, 2008 -
PharmaVoice Team/PharmaVoice
What's New
NEW HEALTHCARERELATED PRODUCTS, SERVICES, AND COMPANIES Publicis Selling Solutions Group has created a new divi sion, Publicis Clinical Health Partners, focused on providing integrated behaviorally based education programs for patients and healthcare professionals to optimize patient compliance a...
By PharmaVoice Team • March 29, 2008 -
PharmaVoice Team/PharmaVoice
PharmaTrax
GOLD STANDARD IN ASTHMA TREATMENT is Expected to Emerge A report by Decision Resources projects that for moterol/mometasone, an asthma therapy codevel oped by ScheringPlough and Novartis, will be approved in 2009 and become the clinical gold standard for treating asthma by 2011 because of its com...
By PharmaVoice Team • March 29, 2008 -
PharmaVoice Team/PharmaVoice
25 Years of the Orphan Drug Act
Synthetic drugs accounted for 62% of total orphan drug approvals, and synthetic polypep tides and hormones together accounted for 6%. Among biologics, growth hormones and growth factors together have the largest num ber of approvals at 8% of the total. Market approvals received for plasma product...
By Cynthia Borda • March 27, 2008 -
PharmaVoice Team/PharmaVoice
The Softer Side of R&D
Industry experts say the technical competencies of drug development have to be combined with the softer skills of change management and leadership ability. R&D leaders will have to work in global teams to manage the output from their partners. This will require highly trained technical specia...
By Denise Myshko • March 27, 2008 -
PharmaVoice Team/PharmaVoice
Proof of Concept
BENEFITS OF EXPLORATORY INDS In a guidance released in January 2006, the FDA laid out specific approaches for researchers George Mills, M.D., VP, medical imaging consulting, for Perceptive Informatics at Parexel International, agrees that an exploratory IND is an avenue to evaluate the preclinica...
By Denise Myshko • March 27, 2008 -
PharmaVoice Team/PharmaVoice
UpFront
Milestones 20 YEARS OF DISCOVERY Pharmaceutical Research and Manufacturers of America (PhRMA) has marked the 20th anniversary of the Discoverers Award, the highest honor given by PhRMA to scientists who helped discover breakthrough medicines for patients suffering from disease. PhRMA presented th...
By PharmaVoice Team • March 27, 2008 -
PharmaVoice Team/PharmaVoice
Raise Your Voice — Letters
A Missing Link I just finished reading the March article, “Strengthening the Clinical Recruitment Chain,” and it seems to me that you forgot a crucial first step in the process you describe. This would be the establishment of a sound protocol that makes scientific sense and benefits the subject. ...
By PharmaVoice Team • March 27, 2008 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Bogey and Bacall, Rogers and Hammerstein,Ben & Jerry,or closer to home John K. Smith, Thomas Beecham, and Mahlon Kline — great partners who made for great partnerships. In developing this issue, an inadvertent theme developed, one centered around the concept of partner ships. What makes them ...
By PharmaVoice Team • March 27, 2008 -
PharmaVoice Team/PharmaVoice
What's New
weaknesses of a product’s message,” says Howard Ziment, CEO.“What the Messagez approach does is qualify, or even eliminate, much of that debate so product directors and agencies can spend more time and energy being creative.” The Messagez approach involves several phases.First, it assures the cre...
By PharmaVoice Team • March 19, 2008 -
PharmaVoice Team/PharmaVoice
On the Calendar
September 1819,2003,Westin Princeton — Princeton,N.J. 2nd Annual Edetailing The Center for Business Intelligence’s eDetailing confer ence will provide an interactive forum to discuss how this innovative tool allows companies to access more physicians and ultimately increase sales. For more inform...
By PharmaVoice Team • March 19, 2008 -
PharmaVoice Team/PharmaVoice
PharmaTrax
76 S e p t e m b e r 200 3 PharmaVOICE Johnson & Johnson is TOP PHARMA COMPANY IN LONGTERM CARE Johnson & Johnson has been selected as the best overall pharmaceutical company by longte rm care (LTC) pharmacists participating in Verispan’s spring 2003 Nursing Home PharmacyProvider/Con sult...
By PharmaVoice Team • March 19, 2008 -
PharmaVoice Team/PharmaVoice
Joseph F. Donahue-Destined for Science
Destined for Science As one of the new breed of 40something business leaders, Joseph F. Donahue is bringing a multidiscipline skill set to help LION bioscience become the leader in improving research productivity within the lifesciences industry. BY KIM RIBBINK 64 S e p t e mb e r 2003 PharmaVOIC...
By Kim Ribbink • March 19, 2008 -
PharmaVoice Team/PharmaVoice
The Great Divide
58 S e p t e mb e r 2003 PharmaVOICE ALL TOO OFTEN MARKETING AND R&D ARE AT ODDS ON HOW TO BEST ALLOCATE RESOURCES TO SUPPORT THE PIPELINE.THIS DISCONNECT BETWEEN SALES AND SCIENCE THREATENS THE FUTURE OF THE PHARMACEUTICAL INDUSTRY. The GREATDivide IN AN EXCLUSIVETO PHARMAVOICE, MICHAEL MENA...
By PharmaVoice Team • March 19, 2008 -
PharmaVoice Team/PharmaVoice
A Temporary Solution
50 S e p t e mb e r 2003 PharmaVOICE clinical trial staffing A T E M P O R A R Y S O L U T I O N the days of temps as lowwage, lowstatus secretaries without benefits have passed. Now highly specialized — and often highly paid — scientists and oth ers involved in clinical research are joining the ...
By PharmaVoice Team • March 19, 2008 -
PharmaVoice Team/PharmaVoice
Opinions
8 S e p t e mb e r 2003 PharmaVOICE other incentives. It was only a matter of time before customer rewards led to increased demands from all business categories, includ ing pharmaceuticals and healthcare. Another trend in healthcare is the increasing portion of the healthcare bill being demanded ...
By PharmaVoice Team • March 18, 2008 -
PharmaVoice Team/PharmaVoice
Raise Your Voice — Letters
6 S e p t e m b e r 2003 PharmaVOICE RAISE your voice Few lessons learned I am writing to offer my feedback about the article “The Lessons of Greed” in the July 2003 issue of PharmaVOICE. As a clinicalresearch professional involved with ensuring the ethical conduct of clinical trials, I have clos...
By PharmaVoice Team • March 18, 2008 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
PUBLISHER Lisa Banket EDITOR Taren Grom CREATIVE DIRECTOR Marah Walsh DIRECTOR OF SALES Darlene Kwiatkowski MANAGING EDITOR Denise Myshko CONTRIBUTING EDITORS Elisabeth Pena Kim Ribbink Lynda Sears Copyright 2003 by PharmaLinx LLC, Titusville, NJ Printed in the U.S.A. Volume Three, Number Nine Ph...
By Taren Grom • March 18, 2008 -
PharmaVoice Team/PharmaVoice
Global Opportunities
According to Ernst & Young, the sheer volume and growing economic muscle of consumers in emerging markets provide powerful investment incentives for multinational companies (MNCs). In particular, current and projected growth rates for pharmaceutical markets in the BRIC countries and Mexico ex...
By Robin Robinson • March 2, 2008
Previous
